Thrombocythemia

Research

Mayo Clinic has conducted a large retrospective study looking at the survival of patients with ET. Mayo researchers have been instrumental in defining diseases related to ET. Researchers are also interested in studying whether certain therapies affect outcome in a positive or negative way. Currently, Mayo Clinic has grants from the Myeloproliferatic Foundation and the National Cancer Institute for studying these types of diseases. In the last two to three years, Mayo Clinic has conducted approximately 10 different clinical trials pertaining to myeloproliferative diseases.

Select Publications

Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematologica 2002; 108(2):55-65. [Abstract]

Mesa RA, Hanson CA, Li CY, Yoon SY, Rajkumar SV, Schroeder G., Tefferi A. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood. 2002 June 1;99(11)4131-7. [Abstract]

Solberg LA. Therapeutic options for essential thrombocythemia and polycythemia vera. Seminars in Oncology 2002 June; 29(3 Suppl 10):10-5. [Abstract]

Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001 Feb 15;97(4):863-6. [Abstract]

Tefferi A. Recent progress in the pathogenesis and management of essential thrombocythemia. Leukemia Research 2001 May; 25(5):369-77. [Abstract]